We focus on the development of novel medicines using our proprietary Extreme Genetics® platform.
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short
November 12, 2015 – Xenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference
November 10, 2015 – Xenon Reports Q3 2015 Financial Results and Provides Corporate Update
November 5, 2015 – Xenon to Host Conference Call and Webcast to Discuss Q3 2015 Financial Results and Provide Corporate Update
October 22, 2015 – Xenon Announces its Partner Genentech has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, into Clinical Development